IL210696A - A method for evaluating the effectiveness of a memory factor that can be primed in improving long-term memory - Google Patents

A method for evaluating the effectiveness of a memory factor that can be primed in improving long-term memory

Info

Publication number
IL210696A
IL210696A IL210696A IL21069611A IL210696A IL 210696 A IL210696 A IL 210696A IL 210696 A IL210696 A IL 210696A IL 21069611 A IL21069611 A IL 21069611A IL 210696 A IL210696 A IL 210696A
Authority
IL
Israel
Prior art keywords
memory
primate
assessing
effectiveness
long term
Prior art date
Application number
IL210696A
Other languages
English (en)
Hebrew (he)
Other versions
IL210696A0 (en
Original Assignee
Dart Neuroscience Cayman Ltd
Dart Neuroscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dart Neuroscience Cayman Ltd, Dart Neuroscience Llc filed Critical Dart Neuroscience Cayman Ltd
Publication of IL210696A0 publication Critical patent/IL210696A0/en
Publication of IL210696A publication Critical patent/IL210696A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/06—Methods of screening libraries by measuring effects on living organisms, tissues or cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL210696A 2008-07-18 2011-01-17 A method for evaluating the effectiveness of a memory factor that can be primed in improving long-term memory IL210696A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8194508P 2008-07-18 2008-07-18
PCT/US2009/051082 WO2010009453A1 (en) 2008-07-18 2009-07-17 Methods and systems for evaluating memory agents

Publications (2)

Publication Number Publication Date
IL210696A0 IL210696A0 (en) 2011-03-31
IL210696A true IL210696A (en) 2014-12-31

Family

ID=41550744

Family Applications (1)

Application Number Title Priority Date Filing Date
IL210696A IL210696A (en) 2008-07-18 2011-01-17 A method for evaluating the effectiveness of a memory factor that can be primed in improving long-term memory

Country Status (11)

Country Link
EP (1) EP2313098A4 (ja)
JP (1) JP5789511B2 (ja)
KR (1) KR20110049801A (ja)
CN (1) CN102143749A (ja)
AU (1) AU2009270697A1 (ja)
BR (1) BRPI0916228A2 (ja)
CA (1) CA2730940A1 (ja)
IL (1) IL210696A (ja)
MX (1) MX2011000652A (ja)
SG (1) SG195572A1 (ja)
WO (1) WO2010009453A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8277842B1 (en) 2012-01-20 2012-10-02 Dart Neuroscience (Cayman) Ltd. Enteric-coated HT-2157 compositions and methods of their use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770658B2 (en) * 1998-09-09 2004-08-03 Inflazyme Pharmaceuticals Ltd. Substituted γ-phenyl-Δ-lactams and uses related thereto
AU3526400A (en) * 1999-03-12 2000-09-28 Brown University Research Foundation Methods and compositions for regulating memory consolidation
ES2323940T3 (es) * 2000-05-01 2009-07-28 Accera, Inc. Uso de trigliceridos de cadena media para el tratamiento y prevencion de la enfermedad de alzheimer.
US20070179197A1 (en) * 2000-05-01 2007-08-02 Accera, Inc. Compositions and methods for improving or preserving brain function
JP2002020291A (ja) * 2000-06-30 2002-01-23 Sumitomo Pharmaceut Co Ltd 認知機能障害の治療剤
EP2305353A1 (en) * 2000-08-10 2011-04-06 Cold Spring Harbor Laboratory Augmented cognitive training
US20040224316A1 (en) * 2000-08-10 2004-11-11 Tully Timothy P. Augmented cognitive training
EP1551855B1 (en) * 2002-06-25 2012-01-04 Helicon Therapeutics, Inc. Altering memory by affecting staufen function
US7642281B2 (en) * 2002-08-07 2010-01-05 Helicon Therapeutics, Inc. Indolone compounds useful to treat cognitive impairment
ES2459042T3 (es) * 2002-08-19 2014-05-07 Dart Neuroscience (Cayman) Ltd Métodos de detección de potenciadores cognitivos
BRPI0619905A2 (pt) * 2005-12-15 2011-10-25 Nestec Sa composições e métodos para conservar função cerebral
EP2500017B1 (en) * 2006-04-03 2017-09-06 Accera, Inc. Use of ketogenic compounds for treatment of age-associated memory impairment
MX2008014713A (es) * 2006-05-19 2009-04-17 Helicon Therapeutics Inc Inhibidores de fosfodiesterasa 4 para rehabilitacion cognitiva y motora.
GB0611458D0 (en) * 2006-06-09 2006-07-19 Univ Cambridge Tech Assessment of functional status
AU2007265088B2 (en) * 2006-06-26 2013-05-23 Dart Neuroscience (Cayman) Ltd Method of modulating neurite outgrowth by the use of a galanin-3 receptor antagonist

Also Published As

Publication number Publication date
AU2009270697A1 (en) 2010-01-21
WO2010009453A1 (en) 2010-01-21
BRPI0916228A2 (pt) 2015-11-03
MX2011000652A (es) 2011-06-16
CN102143749A (zh) 2011-08-03
JP5789511B2 (ja) 2015-10-07
JP2011528667A (ja) 2011-11-24
SG195572A1 (en) 2013-12-30
EP2313098A4 (en) 2011-12-21
EP2313098A1 (en) 2011-04-27
KR20110049801A (ko) 2011-05-12
IL210696A0 (en) 2011-03-31
CA2730940A1 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
EP2308459A4 (en) TOPIC AGENT FOR OIL TYPE SKIN IN WATER
GB0811335D0 (en) Improvements in or relating to amphibians
EP2291159A4 (en) METHOD FOR LIMITING THE CORROSION OF A SENSOR IN ABSORBENT ARTICLES
GB0603464D0 (en) Improvements in & relating to external neurostimulation
EP2250222A4 (en) WATER ABSORPTION AGENT AND METHOD FOR MANUFACTURING THE SAME
EP2257592A4 (en) REDUCTION OF AMINE ALDEHYDES
IL193481A0 (en) 4-phenyl-thiazole-5-carboxylic acids and 4 - phenyl - thiazole - 5 - carboxylic acid amides as plk1 inhibitors
ZA201102690B (en) Amide compounds useful in therapy
ZA201103583B (en) Methods for inhibiting corrosion in aqueous media
IL207127A0 (en) Aldh-2 inhibitors in the treatment of addiction
EP2351558A4 (en) THERAPEUTIC AGENT AGAINST TYMPANITES IN REPURITISHES
EP2286828A4 (en) MEANS TO TREAT NEUROGENIC PAIN
IL210696A (en) A method for evaluating the effectiveness of a memory factor that can be primed in improving long-term memory
GB0725347D0 (en) Improvements in or relating to pipeine pigs
EP2345649A4 (en) BENZIMIDAZOLE COMPOUND IN CRYSTALLINE FORM AND SALT THEREOF
GB2457373B (en) Improvements in or relating to radiator assemblies
GB0816766D0 (en) Improvements in or relating to storage
GB0816764D0 (en) Improvements in or relating to storage
GB0816763D0 (en) Improvements in or relating to storage
GB0806837D0 (en) Improvements in or relating to storage
GB0806829D0 (en) Improvements in or relating to storage
GB0607577D0 (en) Improvements in or relating to storage
GB0619077D0 (en) Improvements in or relating to storage
GB0619076D0 (en) Improvements in or relating to storage
GB0607575D0 (en) Improvements in or relating to storage

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees